FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q54352382> ?p ?o ?g. }

• Q54352382 description "2014 nî lūn-bûn" @default.
• Q54352382 description "2014年の論文" @default.
• Q54352382 description "2014年学术文章" @default.
• Q54352382 description "2014年学术文章" @default.
• Q54352382 description "2014年学术文章" @default.
• Q54352382 description "2014年学术文章" @default.
• Q54352382 description "2014年学术文章" @default.
• Q54352382 description "2014年學術文章" @default.
• Q54352382 description "2014年學術文章" @default.
• Q54352382 description "2014年學術文章" @default.
• Q54352382 description "2014年學術文章" @default.
• Q54352382 description "2014年學術文章" @default.
• Q54352382 description "2014年學術文章" @default.
• Q54352382 description "2014년 논문" @default.
• Q54352382 description "article científic" @default.
• Q54352382 description "article scientific" @default.
• Q54352382 description "article scientifique (publié 2014)" @default.
• Q54352382 description "articol științific" @default.
• Q54352382 description "articolo scientifico" @default.
• Q54352382 description "artigo científico (publicado na 2014)" @default.
• Q54352382 description "artigo científico (publicado na 2014)" @default.
• Q54352382 description "artigo científico" @default.
• Q54352382 description "artikull shkencor" @default.
• Q54352382 description "artikulong pang-agham" @default.
• Q54352382 description "artykuł naukowy" @default.
• Q54352382 description "artículo científico publicado en 2014" @default.
• Q54352382 description "artículu científicu" @default.
• Q54352382 description "bilimsel makale" @default.
• Q54352382 description "bài báo khoa học" @default.
• Q54352382 description "mokslinis straipsnis" @default.
• Q54352382 description "naučni članak" @default.
• Q54352382 description "scienca artikolo" @default.
• Q54352382 description "scientific article" @default.
• Q54352382 description "teaduslik artikkel" @default.
• Q54352382 description "tieteellinen artikkeli" @default.
• Q54352382 description "tudományos cikk" @default.
• Q54352382 description "vedecký článok" @default.
• Q54352382 description "vetenskaplig artikel" @default.
• Q54352382 description "videnskabelig artikel (udgivet 2014)" @default.
• Q54352382 description "vitenskapelig artikkel" @default.
• Q54352382 description "vitskapeleg artikkel" @default.
• Q54352382 description "vědecký článek" @default.
• Q54352382 description "wetenschappelijk artikel" @default.
• Q54352382 description "wissenschaftlicher Artikel" @default.
• Q54352382 description "επιστημονικό άρθρο" @default.
• Q54352382 description "мақолаи илмӣ" @default.
• Q54352382 description "мақолаи илмӣ" @default.
• Q54352382 description "наукова стаття, опублікована у квітні 2014" @default.
• Q54352382 description "научна статия" @default.
• Q54352382 description "научная статья" @default.
• Q54352382 description "научни чланак" @default.
• Q54352382 description "научни чланак" @default.
• Q54352382 description "գիտական հոդված" @default.
• Q54352382 description "מאמר מדעי" @default.
• Q54352382 description "سائنسی مضمون" @default.
• Q54352382 description "مقالة علمية" @default.
• Q54352382 description "مقالهٔ علمی" @default.
• Q54352382 description "২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q54352382 description "บทความทางวิทยาศาสตร์" @default.
• Q54352382 description "სამეცნიერო სტატია" @default.
• Q54352382 name "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." @default.
• Q54352382 name "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." @default.
• Q54352382 type Item @default.
• Q54352382 label "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." @default.
• Q54352382 label "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." @default.
• Q54352382 prefLabel "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." @default.
• Q54352382 prefLabel "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." @default.
• Q54352382 P1433 Q54352382-288510CF-8179-4006-A0E8-DBBD746BD63A @default.
• Q54352382 P1476 Q54352382-260D042B-9886-4C13-8828-07D43AF43555 @default.
• Q54352382 P2093 Q54352382-13CC8D42-2D71-472A-935B-FB96B26A01D4 @default.
• Q54352382 P2093 Q54352382-1E599336-A61C-464D-A504-5F737CBD80BB @default.
• Q54352382 P2093 Q54352382-20E4A011-5157-44A4-A215-FCD3B2BF14D2 @default.
• Q54352382 P2093 Q54352382-45F2614E-80C5-481F-8F54-458EC4FFC384 @default.
• Q54352382 P2093 Q54352382-8F8CBA2F-E7DE-4B40-B8BD-3F4ED718A310 @default.
• Q54352382 P2093 Q54352382-AF0AE9AF-6147-4137-9F1E-AE379C966B9C @default.
• Q54352382 P2093 Q54352382-B7725178-83BE-4A1B-89E3-3C349F629F61 @default.
• Q54352382 P2093 Q54352382-E3710B9D-233E-4CFC-B110-ACAAB990ED94 @default.
• Q54352382 P304 Q54352382-4E50DD81-2370-47C1-BA21-A68FCA056D16 @default.
• Q54352382 P31 Q54352382-A7D95372-0CDF-4F72-A02A-E9229210B164 @default.
• Q54352382 P356 Q54352382-0C293FE8-932A-41EC-A7EC-87C86365846D @default.
• Q54352382 P433 Q54352382-0849BECE-7598-48A6-A386-00C18C1D112A @default.
• Q54352382 P478 Q54352382-41055759-92A6-41A9-B3F5-856B27EDFF49 @default.
• Q54352382 P50 Q54352382-0791DE95-2ECD-414F-818B-72B8BF1FDC8E @default.
• Q54352382 P50 Q54352382-56922AB1-BAB3-4FBB-BCD8-7AA2757F0B39 @default.
• Q54352382 P50 Q54352382-6FDD2316-558F-428A-8A4B-4D72895D1320 @default.
• Q54352382 P50 Q54352382-C1B8F696-0991-40C4-BB28-92DD5DDC866C @default.
• Q54352382 P50 Q54352382-DE132CA1-49E5-48CD-91FD-977198DEADDB @default.
• Q54352382 P50 Q54352382-FFA7A021-43FE-4201-96BA-F6757C7A450D @default.
• Q54352382 P577 Q54352382-C6D5EABD-27D0-45D7-A4C3-3652712DC32E @default.
• Q54352382 P5875 Q54352382-1D12DF8E-3CFE-463F-8205-2BCDE02599DA @default.
• Q54352382 P698 Q54352382-1B69CEBD-E131-475B-814C-85178746F8C1 @default.
• Q54352382 P921 Q54352382-186DCFCF-2F79-4621-9A0E-1A466FAD63E1 @default.
• Q54352382 P921 Q54352382-3FE2239B-3AF9-44E1-B645-DB5B3A02176A @default.
• Q54352382 P921 Q54352382-C10099D5-7338-4FBC-A963-3A3249C6CC3C @default.
• Q54352382 P921 Q54352382-E67A06FD-1995-4B6D-ABA2-A16A6DB62D0D @default.
• Q54352382 P356 J.LEUKRES.2014.04.004 @default.
• Q54352382 P698 24832371 @default.
• Q54352382 P1433 Q15716445 @default.
• Q54352382 P1476 "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." @default.
• Q54352382 P2093 "Ayse Salihoglu" @default.

• next